Granules India inches up on getting USFDA nod for naproxen sodium tablet

26 Sep 2011 Evaluate

Granules India is currently trading at Rs. 66.60, up by 0.05 points or 0.08% from its previous closing of Rs. 66.55 on the BSE.

The scrip opened at Rs. 67.80 and has touched a high and low of Rs. 67.80 and Rs. 66.00 respectively. So far 1005 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 116.55 on 15-Oct-2010 and a 52 week low of Rs. 65.30 on 19-Aug-2011.

Last one week high and low of the scrip stood at Rs. 68.00 and Rs. 65.50 respectively. The current market cap of the company is Rs. 133.51 crore.

The promoters holding in the company stood at 40.70% while Institutions and Non-Institutions held 1.49% and 55.09% respectively.

Granules India has received approval from the US Food and Drug Administration (FDA) for its naproxen sodium tablet, the generic version of Bayer AG’s Aleve pain relieving medicine,

The company is producer of active pharmaceutical ingredients (API's) and pharmaceutical formulation intermediates (PFIs) with complete vertical integration. They expertise in manufacturing PFIs which are Directly Compressible Granules has helped customers to move to the next level of outsourcing in the pharmaceutical industry.

Granules India Share Price

398.60 6.55 (1.67%)
10-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1505.20
Dr. Reddys Lab 5922.45
Cipla 1339.45
Zydus Lifesciences 983.05
Lupin 1609.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.